Literature DB >> 7161762

Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes.

K Mehta, G Lopez-Berestein, E M Hersh, R L Juliano.   

Abstract

The interaction of multilamellar liposomes with human peripheral blood monocytes, cultured in vitro, has been examined. Phagocytic engulfment is the principal mechanism by which the liposomes are taken up by these cells. Studies with radiolabeled liposomes revealed that they are taken up by monocytes as intact structures. The uptake is temperature sensitive and is affected by inhibitors of glycolysis and of microfilament activity. Monocytes take up negatively charged vesicles more rapidly than positively charged (3-fold) vesicles or neutral vesicles (5-fold). Increase in negative charge of liposomes enhances their uptake by the cells, but increased saturation of the phospholipids results in decreased uptake. Liposomes provide an effective means of enhancing the uptake of MDP derivatives (3H nor MDP) by monocytes, with a 20-fold greater uptake of liposome encapsulated drug than of the free compound. Monocytes do not degrade the 3H-nor MDP that they have internalized and radiolabel is only slowly released from the cells. These observations suggest a pharmacokinetic basis for the use of lipid vesicles as a system for the delivery of immunomodulating drugs to monocytes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7161762

Source DB:  PubMed          Journal:  J Reticuloendothel Soc        ISSN: 0033-6890


  15 in total

Review 1.  Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome.

Authors:  Ximing Li; Hongliang Cong
Journal:  Tex Heart Inst J       Date:  2009

Review 2.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

3.  Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.

Authors:  A F Brownbill; D G Braun; P Dukor; G Schumann
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  The systemic activation of macrophages by liposomes containing immunomodulators.

Authors:  R Nayar; I J Fidler
Journal:  Springer Semin Immunopathol       Date:  1985

Review 5.  Diversity of lipid-based polyene formulations and their behavior in biological systems.

Authors:  K M Wasan; G Lopez-Berestein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

6.  pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling.

Authors:  Jooeun Lee; Ivan Tattoli; Kacper A Wojtal; Stephan R Vavricka; Dana J Philpott; Stephen E Girardin
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

7.  Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites.

Authors:  K Mehta; R L Juliano; G Lopez-Berestein
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

8.  Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.

Authors:  G Lopez-Berestein; L Milas; N Hunter; K Mehta; E M Hersh; C G Kurahara; M Vandupas; D A Eppstein
Journal:  Clin Exp Metastasis       Date:  1984 Apr-Jun       Impact factor: 5.150

9.  In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362.

Authors:  T Utsugi; C P Dinney; J J Killion; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.

Authors:  T Utsugi; A Nii; D Fan; C C Pak; Y Denkins; P van Hoogevest; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.